High hopes are riding on a new generation of tiny pacemakers, but the Minnesota med-tech companies that make them will be working this week to convince medical experts that the devices can be safely tested and eventually extracted from patients' hearts.
Dan Starks, who will step aside at the end of the year as CEO of St. Jude Medical, doesn't spend his time the way some CEOs of other big companies he's observed do, being what he called "administrators."
Little Canada medical device maker St. Jude Medical announced a definitive agreement Wednesday to acquire California heart-device firm Thoratec for $3.4 billion. The deal, the largest ever for St. Jude, is expected to close by the end of the year.
Physicians, and some stock analysts, are closely watching the safety profile of tiny novel pacemakers like the Nanostim in ongoing studies. Implants of the device have been halted in Europe after several became dislodged.